PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs NVS |
|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 0.12 | 17.8 | 149.5% | -92% |
| AZN | AstraZeneca PLC | 0.21 | 12.7 | 61.0% | -86% |
| GSK | GSK plc | 0.99 | 14.3 | 14.4% | -35% |
| LLY | Eli Lilly and Company | 1.55 | 42.6 | 27.5% | +1% |
| MRK | Merck & Co., Inc. | 1.74 | 36.8 | 21.2% | +14% |